On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Taixing site officially started. Located in Taixing Economic Development Zone, Jiangsu China, Taixing campus will become another integrated API R&D and manufacturing site for WuXi STA, further strengthening its world-leading Chemistry, Manufacturing and Control (CMC) platform for innovative drugs, empowering more partners to launch more therapies faster.
With a total area of 170 acres, Taixing site is designed to support global partners with integrated API process R&D and manufacturing from preclinical to commercial stages. The first phase of the project, with an area of about 53 acres, is expected to be fully operational in 2025, with an annual capacity of more than 100 metric ton drug substance. The first phase of the project also includes industry-leading new molecular modality platforms from laboratory to commercial scale, such as high potency APIs, oligonucleotides and peptides. In addition, Taixing site reserved enough space for the second and third phases of the construction committed for future expansion.
Dr. Chen Minzhang, Chief Executive Officer of WuXi STA, commented, "leveraging the excellent local infrastructure and talent resource, Taixing site will further enhance our CDMO platform capability with even more capacities. With the continued development of our end-to-end CMC platform, I believe we can partner with more new drug innovators to bring novel therapies to patients worldwide faster.”
WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) solutions from preclinical to commercial uses. For more information, please visit: http://www.STApharma.com and follow us on LinkedIn.